WALTHAM, Mass. The securities to be sold in the private placement have not been registered under the Securities Act of 1933, as amended (the “Securities Act”), or applicable state securities laws, and accordingly may not be offered or sold in the United States except pursuant to an effective registration statement or an applicable exemption from the registration requirements of the Securities Act and such applicable state securities laws. WALTHAM, Mass., Aug. 28, 2020 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (Nasdaq: ETTX) (“Entasis”), a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibacterial products, announced today it has entered into a definitive agreement to sell securities in a private placement with Innoviva, Inc. (Nasdaq: INVA), a company with a portfolio of royalties, and another healthcare-focused institutional investor. A.G.P./Alliance Global Partners is also acting as a placement agent. Published. Year. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of shares of Entasis’ common stock in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of such state or jurisdiction. Words such as “may,” “will,” “expect,” “plan,” “anticipate,” “estimate,” “intend” and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking … These forward-looking statements are based on Entasis’ expectations and assumptions as of the date of this press release. The gross proceeds to the Company from the private placement, before deducting the placement agent's fees and other estimated offering expenses payable by the Company, are expected to be approximately $25 million. Entasis Forward-looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of … The Company intends to use the net proceeds from the private placement for the continued support of the ongoing ATTACK Phase 3 registration clinical trial as well as for working capital and other general corporate purposes. Each unit consists of approximately one share of common stock and a warrant to purchase one share of common stock at an exercise price of $2.675. Entasis Therapeutics strives towards global advancement by addressing the critical threat of multi-drug resistant bacteria. Entasis Therapeutics was established in 2015 as a spin-out from and with initial funding from AstraZeneca, and all rights to AstraZeneca’s industry-leading discovery and early development small-molecule anti-infectives portfolio. Entasis Therapeutics Announces Sulbactam-Durlobactam Expanded Access Program for Patients in the U.S. Jan 26, 2021. Entasis Forward-looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of … Home > Press Releases Translations Entasis Therapeutics und die Globale Partnerschaft für Antibiotika-Forschung & Entwicklung (GARDP) entwickeln ein neues Antibiotikum zur … Entasis Forward-looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. About EntasisEntasis is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel antibacterial products to treat serious infections caused by multidrug-resistant Gram-negative bacteria. Entasis Forward-looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on Entasis’ expectations and assumptions as of the date of this press release. Sep 10, 2020. This press release does not constitute an offer to sell, or the solicitation of an offer to buy, any security and shall not constitute an offer, solicitation or sale in any jurisdiction in … ATTACK is a global two-part Phase 3 registration trial evaluating SUL-DUR for the treatment of patients with pneumonia and bloodstream infections caused by carbapenem-resistant Acinetobacter baumannii. Words such as “may,” “will,” “expect,” “plan,” “anticipate,” “estimate,” “intend” and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking … Press Releases. entasis betyder spænding og er betegnelsen for de let konvekse, udadbuede kurver på græske søjler. Bloomberg the Company & Its Products The Company & its Products Bloomberg Terminal Demo Request Bloomberg Anywhere Remote Login Bloomberg Anywhere Login Bloomberg Customer Support Customer Support Form10-Q Entasis Therapeutics Holdings Inc. Nov 05,2020 16:33. The private placement is expected to close on or about September 1, 2020, subject to the satisfaction of customary closing conditions. SIGN UP. Certain investors may elect to receive pre-funded warrants to purchase common stock in lieu of a portion of their common stock. Words such as “may,” “will,” “expect,” “plan,” “anticipate,” “estimate,” “intend” and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. Entasis Forward-looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Oct 14, 2020. Press Releases Year. This press release does not constitute an offer to sell or the solicitation of an offer to buy the securities. Find the latest Entasis Therapeutics Holdings (ETTX) press releases from Webull to help you in your trading and investing ETTX decisions. Physicians who are seeking preapproval access to SUL-DUR can submit requests to Expandedaccess@entasistx.com, according to a company press release. Entasis Therapeutics Announces Sulbactam-Durlobactam Expanded Access Program for Patients in the U.S. Entasis Therapeutics to Present at the H.C. Wainwright BioConnect 2021 Conference, Entasis Therapeutics to Participate in A.G.P.’s Virtual Healthcare Symposium, Entasis Therapeutics Reports Third Quarter 2020 Financial Results and Provides a Business Update, Entasis Therapeutics Highlights Multiple Data Presentations at Virtual ID Week, Entasis Therapeutics to Participate in Upcoming Healthcare Investor Conferences, Entasis Therapeutics Announces $25 Million Private Placement, Entasis Therapeutics Reports Second Quarter 2020 Financial Results and Business Update, Entasis Therapeutics to Participate in Upcoming Healthcare Conferences, Entasis Therapeutics Awarded Contract from National Institutes of Health. Entasis’ pathogen-targeted design platform has produced a pipeline of product candidates, including sulbactam-durlobactam (targeting Acinetobacter baumannii infections), zoliflodacin (targeting Neisseria gonorrhoeae infections), ETX0282CPDP (targeting Enterobacteriaceae infections) and ETX0462 (targeting Pseudomonas infections). Any offering of the securities under such resale registration statement will only be by means of a prospectus. Entasis Forward-looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Contact Entasis with comments or questions. Bloomberg the Company & Its Products The Company & its Products Bloomberg Terminal Demo Request Bloomberg Anywhere Remote Login Bloomberg Anywhere Login Bloomberg Customer Support Customer Support HOME MARKET TRADE PRICING DOWNLOAD HELP. Published. Entasis Forward-looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on Entasis’ expectations and assumptions as of the date of this press release. Many factors may cause differences between current expectations and actual results, including the impact of the COVID-19 pandemic, unexpected safety or efficacy data observed during non-clinical or clinical studies, clinical site activation rates or clinical trial enrollment rates that are lower than expected and changes in expected or existing competition, changes in the regulatory environment, failure of Entasis’ collaborators to support or advance collaborations or product candidates and unexpected litigation or other disputes. Entasis Forward-looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Each of these forward-looking statements involves risks and uncertainties. Entasis has agreed to file a registration statement with the United States Securities and Exchange Commission registering the resale of the securities issued in the private placement. None. Gamida Cell Presents Efficacy and Safety Results of Phase 3 Study of Omidubicel in Patients with Hematologic Malignancies at the 47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) March 15, 2021 PDF Version. The name of the press, Entasis, is an architectural term for the delicate and almost imperceptible swelling in the shaft of a column, a device the architects of ancient Greece developed for … Etymology. Actual results may differ materially from these forward-looking statements. entasis er valgt som tegnestuens navn for at påpege, at arkitektur er mere historie og akkumuleret kultur end det er en enkelt persons geniale og isolerede univers. WALTHAM, Mass., July 06, 2020 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibacterial products, today announced it has entered into a contract with the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH). Entasis Forward-looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Its best-known use is in certain orders of Classical columns that curve slightly as their diameter is decreased from the bottom upward. Company Contact Kyle DowEntasis Therapeutics(781) 810-0114 kyle.dow@entasistx.com, Investor Relations ContactsJames SaliernoThe Ruth Group(646) 536-7028jsalierno@theruthgroup.com, Media ContactKirsten ThomasThe Ruth Group(508) 280-6592kthomas@theruthgroup.com. børneinstitutionen i stueetagen på Krøyer Hus i Carlsbergbyen. Releases. None 2021 2020 2019 2018 2017 2016 2015 2014. Our pipeline consists of clinical and pre-clinical pathogen-targeted small-molecule antibacterials for the treatment of multidrug-resistant Gram-negative bacteria, such as Pseudomonas aeruginosa, Acinetobacter baumanii, carbapenem-resistant Enterobacteriaceae, and … LOG IN. Nov 5, 2020. ETX2514SUL was generally well tolerated. Subscribe to our news wire by filling out the confidential sign-up form. In architecture, entasis is the application of a convex curve to a surface for aesthetic purposes. Forward-looking statements contained in this announcement are made as of this date, and except as required by law, Entasis assumes no obligation to update any forward-looking statements contained herein to reflect any change in expectations, even as new information becomes available. Entasis … View HTML. For more information, visit www.entasistx.com. It also may serve an engineering function regarding strength. About Entasis Therapeutics. Entasis Forward-looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Get the latest Entasis Therapeutics Holdings I (ETTX) stock news and headlines to help you in your trading and investment decisions. Published. Cantor Fitzgerald & Co. is acting as the lead placement agent for the private placement. Many of these factors are beyond Entasis’ control. Entasis Therapeutics Highlights Multiple Data Presentations at Virtual ID Week. These and other risks and uncertainties are described more fully in the Entasis’ filings with the U.S. Securities and Exchange Commission, including the section titled “Risk Factors” contained therein. Jan 07, 2021. Entasis Forward-looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Source: Entasis Therapeutics Holdings Inc. Entasis Therapeutics Announces $25 Million Private Placement. ETTX--0.00%--All; Financials ; Insiders; Form8-K Entasis Therapeutics Holdings Inc. Nov 06,2020 16:01. Entasis Therapeutics to Present at the H.C. Wainwright BioConnect 2021 Conference. Oct 14, 2020. Since receiving our funding from AstraZeneca, we have raised $81.9 million in gross proceeds from equity financings from several U.S. and European healthcare specialist … Entasis Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. WALTHAM, Mass., July 06, 2020 -- Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel.
Bastei Verlag Sucht Autoren,
Deutsche Aussprache Hören,
Praktikum Pflege Berlin,
Produkte Aus Düsseldorf,
Ebay Kleinanzeigen Cham Auto,
Erich Kästner Vorstadtstraßen Interpretation,